ASCO 2023: AI-Derived Digital Pathology Biomarker Predicts Benefit of Long-Term ADT with Radiotherapy in Localized High-Risk Prostate Cancer
Dr. Andrew J. Armstrong presented the results of a pooled analysis of multiple phase III NRG/RTOG trials aimed at developing [...]
ArteraAI Presents New Data Validating AI-Derived Predictive Biomarker at 2023 ASCO Annual Meeting
The biomarker is the first to predict long-term ADT usage in men with high-risk localized prostate cancer.
Dr. McKay highlights the ArteraAI Prostate Test
In this interview, Dr. McKay discusses use of the ArteraAI test for prostate cancer risk stratification. Dr. McKay is a GU me [...]
Mack Roach, MD, FASTRO, FASCO
Dr. Roach discusses how the performance of the multimodal artificial intelligence (MMAI)-derived prognostic biomarker is comp [...]
Daniel Spratt, MD
Dr. Spratt discusses the validation of an MMAI prognostic biomarker and how the model further stratifies risk in men with hig [...]
Osama Mohamad, MD
Dr. Mohamad discusses the development and validation of a multimodal artificial intelligence (MMAI)-derived prognostic biomar [...]
Daniel Spratt, MD
Dr. Spratt discusses the validation of an MMAI prognostic biomarker and how the model further stratifies risk in men with hig [...]
Ashley Evan Ross, MD, PHD
Dr. Ross discusses external validation of an MMAI prognostic model in patients with high- and very high-risk disease. Additio [...]
Felix Feng, MD
Dr. Feng discusses the development and validation of pathology-based deep learning predictive and prognostic tools to persona [...]